MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why TECX Stock slipped -0.29% Today — RQD Quant Desk Flash
$20.50 -0.29% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $20.45
Tectonic Therapeutic Inc. (TECX) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $400.8M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $20.45 (-0.24%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-9.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TECX)Realized 20D OHLCV Swing Band: ±11.6%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY TECX SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (22% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$23.33-11.5% Next Q
45
Q2 (-2Q)Grade D$20.65-2.8% Next Q
42
Q3 (-1Q)Grade D$20.07+2.1% Next Q
40
CurrentGrade D-$20.50-8.1% Hist 90D α
37
Trajectory: D (45) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a TECX Turnaround Squeeze
While TECX currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($26.01) and Max Pain ($21.53) forces dealer call-delta covering toward $41.51.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $TECX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TECX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why TECX Stock slipped -0.29% Today — RQD Quant Desk Flash
Tectonic Therapeutic Inc. (TECX) slipped -0.29% to $20.50, trading at 21% of its 52-week range ($15.52 – $39.53). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 21% of its 52-week range ($15.52 – $39.53) with RSI-14 at 30.8 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.6% around $20.50 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live TECX Headlines & Catalysts
MARKET WIRECNBC • 2h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 6h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TECX)
- ✓Walkthrough of TECX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
TECX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.71%▼ SUPPORT BREAKDOWN
2026-10-30O $20.51H $20.51L $19.56C $20.50VOL 146.3K
RES: $38.00SUP: $27.62SMA50: $26.01SMA200: $28.09
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
TECX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on TECX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for TECX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TECX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TECX)
Health Care Rank #749 of 1016
⚔️ CCCC vs TECX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (TECX vs. CCCC, AGMB, FENC, AUTL)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Tectonic Therapeutic Inc. (TECX) ranks #749 by composite RQD confidence (37/100, grade D-) and #479 by equity capitalization ($400.8M). Within this direct 5-issuer industry benchmark cohort, TECX leads on earnings valuation at N/A trailing P/E, while FENC leads on capital efficiency and profitability with -25.9% ROIC and — gross margin. AGMB currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with TECX at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TECX
ACTIVE
Tectonic Therapeutic Inc. | D- | 37/100 | — | — | -35.0% | -0.29% | $400.8M | Benchmark Subject |
| CCCC C4 Therapeutics Inc. | E | 27/100 | — | — | -35.0% | -2.80% | $406.0M | /cccc-vs-tecx → |
| AGMB AgomAb Therapeutics NV | D | 51/100 | — | — | — | -0.13% | $391.5M | /agmb-vs-tecx → |
| FENC Fennec Pharmaceuticals Inc. | D- | 36/100 | — | — | -25.9% | +0.74% | $383.6M | /fenc-vs-tecx → |
| AUTL Autolus Therapeutics plc | E | 25/100 | — | -27.8% | -35.0% | -3.07% | $420.5M | /autl-vs-tecx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001681087In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tectonic Therapeutic Inc. (TECX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$74.15B, operating cash flow of -$60.1M, and free cash flow of -$60.3M (-1.8% YoY). On the balance sheet, TECX closed FY2025 with $261.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$74.15B | -$60.1M | -$60.3M | $261.0M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$57.98B | -$59.1M | -$59.2M | $152.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$42.82B | -$40.7M | -$40.7M | — | — |
3. TECX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs TECX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Tectonic Therapeutic Inc. (NASDAQ: TECX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $20.50 (-0.29% 1D, market cap $400.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TECX ranks #749 in composite RQD confidence.
How does TECX compare to CCCC and AGMB in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TECX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CCCC (C4 Therapeutics Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $406.0M) and AGMB (AgomAb Therapeutics NV) posts a D grade (51/100 RQD, P/E N/A, ROIC —, cap $391.5M). Among the 5-stock peer group, TECX leads on earnings multiple (N/A) while FENC leads on capital efficiency (-25.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for TECX?
Per TECX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001681087), Tectonic Therapeutic Inc. generated $0 in revenue, -$74.15B in net income, and -$60.3M in free cash flow against $261.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is TECX trading relative to its 50-day, 200-day, and 52-week technical levels?
TECX last traded at $20.50 (-0.29% on volume of 139,609 shares), positioning the stock -21.18% below its 50-day simple moving average ($26.01) and -27.02% below its 200-day simple moving average ($28.09). Across its 52-week range of $15.52 to $39.53, TECX sits at the 20.7% percentile with a 14-day RSI of 30.8 (OVERSOLD (<32)) and an implied next-earnings move of ±11.6% ($18.12 to $22.88).
TECX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is TECX stock moving today?
Why TECX Stock slipped -0.29% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.